|Articles|November 1, 2022
Supplements and Featured Publications
- Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update
- Volume 28
- Issue 12
eAppendix: Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys
Advertisement
Articles in this issue
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
2
Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year
3
Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD
4
Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD
5

